Press Release

25 October 2024

Infographic | HitGen FY2024 Q3 Report

Infographic | HitGen FY2024 Q3 Report
08 October 2024

Pharma Peers Unite to Build DNA-Encoded Libraries

Finding tools and hits for targets in drug discovery can feel like hunting for four leaf clovers in a blizzard. And researcher Sylvie Sakata was close to giving up on one discovery tool, DNA-encoded libraries, when a new consortium started to fall into place. Now this technology is garnering more interest for its potential to discover new molecular compounds, known as “hits,” to exponentially impact the early research efforts that can lead to potential new medicines.
28 August 2024

Infographic | HitGen FY2024H1 Report

Infographic | HitGen FY2024H1 Report
22 August 2024

Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program

CHENGDU, China, August 22, 2024 – Bridge Biotherapeutics ("Bridge", KQ288330), a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc. ("HitGen", SSE: 688222.SH), a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen’s DNA-encoded library (DEL), aiming to further develop the novel hits as promising drug candidates for cancer.
24 April 2024

Infographic | HitGen FY2023&2024Q1 Report

Infographic | HitGen FY2023&2024Q1 Report
08 April 2024

Vernalis announces a drug discovery collaboration with C4X Discovery in inflammatory disease

Vernalis (R&D) Limited (“Vernalis”), a wholly owned subsidiary of HitGen Inc., and C4X Discovery (“C4XD”) are pleased to announce a collaboration to identify modulators of an undisclosed high-value target involved in inflammatory disease.
26 March 2024

HitGen Partners with LabCentral / BioLabs / MBC BioLabs to Accelerate Biotechnology Discovery

[San Francisco, CA – March 25, 2024] – LabCentral, a launchpad for high-potential life science and biotech start-ups, BioLabs, an international membership-based network of shared lab and office facilities, and MBC BioLabs, premier providers of co-working laboratory space, announced a partnership with HitGen, a global leader in the design, synthesis, and screening of DNA-encoded chemical libraries (DELs).
21 February 2024

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

Hox Therapeutics Ltd (“Hox”) a private biotechnology company developing highly targeted cancer therapies and Vernalis (R&D) Ltd (“Vernalis”), a fully owned subsidiary of HitGen Inc., are pleased to announce a collaboration to identify inhibitors against an undisclosed oncology target.
13 November 2023

Get ready for the end-of-year sale! Discover the future of drug discovery with OpenDEL™ and save 20% off!
27 October 2023

Infographic | HitGen FY2023 Q3 Report

News

Press Release

Thanks for reading!